| Document |
Document Title |
|
WO/2022/142150A1 |
A clindamycin phosphate vaginal tablet, which is prepared from the following raw materials in parts by weight: 125 parts of clindamycin phosphate, 140-160 parts of lactose, 90-95 parts of microcrystalline cellulose, 7-8 parts of sodium s...
|
|
WO/2022/146061A1 |
Provided is a pharmaceutical composition comprising as active ingredients: 5mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution r...
|
|
WO/2022/142385A1 |
The present invention provides a method for refining dienogest. The method is a recrystallization method. The present invention belongs to the technical field of medicine synthesis. The refining of dienogest comprises the following steps...
|
|
WO/2022/143489A1 |
A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxi...
|
|
WO/2022/141441A1 |
Provided is a follicle-stimulating hormone (FSH). The preparation thereof comprises the following steps: introducing a secretion signal peptide into the two subunits FSHα and FSHβ of the FSH, and then individually expressing same, foll...
|
|
WO/2022/139443A1 |
The present invention relates to crystalline form I of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form I of the compound represented by chemica...
|
|
WO/2022/135545A1 |
Provided is use of a cell-free fat extract for preparing a composition or a formulation. The composition or formulation is used for (i) preventing and/or treating erectile dysfunction; and/or (ii) preventing and/or treating corpus cavern...
|
|
WO/2022/139441A1 |
The present invention relates to an amorphous compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The amorphous compound represented by chemical formula 1 of the pres...
|
|
WO/2022/139444A1 |
The present invention relates to a crystal type II of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystal type II of the compound represented by chemica...
|
|
WO/2022/139477A1 |
The present invention provides a medicinal and/or culinary use of an Artemisia annua extract for treating, ameliorating and/or preventing at least one selected from among bone diseases, menopausal disorders, cardiovascular diseases, neur...
|
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
|
WO/2022/140417A1 |
The present disclosure provides a method of treating a sexual dysfunction in a human male subject in need thereof comprising administering an effective amount of a mesembrine alkaloid or salt thereof to the subject in need thereof. Also ...
|
|
WO/2022/139406A1 |
The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/138909A1 |
[Problem] The present invention provides: an equol clathrate having improved solubility in water; an equol-absorbent composition containing the equol clathrate; a production method for the clathrate; and an equol-absorbent composition co...
|
|
WO/2022/139446A1 |
The present invention relates to a crystalline form III of a compound represented by chemical formula 1, a preparation method therefor, and a pharmaceutical composition comprising same. The crystalline form III of the compound represente...
|
|
WO/2022/126179A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to modulate the activity of oxytoci...
|
|
WO/2022/129484A1 |
The present invention relates to a composition for use in the treatment of infertility. The composition of the invention finds utility as a personal lubricant that can be used to increase sperm motility or sperm velocity. Also disclosed ...
|
|
WO/2022/124494A1 |
A pharmaceutical composition according to the present invention comprises a first liquid containing PEG-VS and a second liquid containing a crosslinker inclusive of an amino acid sequence cleaved by a proteinase, wherein the first liquid...
|
|
WO/2022/124311A1 |
[Problem] The purpose of the present invention is to provide an agent capable of enhancing the female hormone-like action of equol. [Solution] The effect of enhancing the female hormone-like action of equol is exhibited as a result of us...
|
|
WO/2022/122899A1 |
Methods using and compositions including FSH for use in the treatment of infertility are described.
|
|
WO/2022/122104A1 |
The present invention relates to methods for predicting the fertility potential of a female subject using RANKL and OPG as biomarkers. The present invention also relates to the use of stimulators of RANKL, inhibitors of RANKL and/or inhi...
|
|
WO/2022/120054A1 |
Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, deuterated androstenedione, or derivatives thereof. The provided compositions and related methods may...
|
|
WO/2022/117828A1 |
The present invention concerns a treatment of polycystic ovary syndrome (PCOS) by using specialized pro-resolving lipid mediators (SPM) or their active precursors, optionally in combination with a non-steroidal anti-inflammatory drug.
|
|
WO/2022/118282A1 |
The present disclosure relates to a composition for use in the treatment or therapy of diseases caused by a peripheral nerve injury, comprising a polymer and a functional group able to bind to an antibody and/or a growth factor, wherein ...
|
|
WO/2022/115581A1 |
The presently disclosed subject matter pertains in some embodiments to methods and compositions for use in the detection, management and/or treatment of endometriosis and/or subfertility/infertility using SIRT1 inhibitor EX-527.
|
|
WO/2022/111543A1 |
Provided are a use of zanamivir in preparation of a drug for treating or preventing preeclampsia and a corresponding drug and treatment method. Zanamivir can effectively improve the symptoms of hypertension, proteinuria, increased creati...
|
|
WO/2022/111581A1 |
A benzazepine spiro derivative as represented by formula (I) and a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/111222A1 |
Disclosed in the present invention are a series of amide derivatives of formula I or pharmaceutically acceptable salts thereof, and a use thereof in serving as prostaglandin E2 receptor 4(EP4) antagonists. The preparation of the amide de...
|
|
WO/2022/107042A1 |
Composition contains sydenafil citrate and tadalafil as active ingredients, and dicalcium phosphate dihydrate, microcrystalline cellulose, starch sodium glycidolate, colloidal silicon dioxide and magnesium stearate – as pharmaceuticall...
|
|
WO/2022/106819A2 |
The present invention provides a pharmaceutical composition for use in the prevention or treatment of a condition associated with a reduction in the number of Lactobacilli in the vagina of a subject relative to a healthy subject, wherein...
|
|
WO/2022/105725A1 |
Disclosed is a preparation method for deer velvet alcohol. The method comprises: freeze-drying fresh deer velvet, adding same into a 40-53 ° alcohol base at a 1:20-500 ratio, utilizing ultrasonic reflux extraction, and after centrifugat...
|
|
WO/2022/106712A1 |
The subject matter of the invention relates to a tetrapeptide which binds to the ZIP9 receptor for the treatment of osteoporosis, myodegenerative diseases, and male infertility. The invention also relates to the use of the tetrapeptide a...
|
|
WO/2022/104413A1 |
Provided herein are compositions, methods and kits for effectively preventing, treating, reducing, mitigating, or controlling female sexual interest and arousal disorder (FSIAD), wherein the method comprises administering to a subject in...
|
|
WO/2022/105998A1 |
Provided are polypeptides, nucleic acids, vectors, cells and compositions useful for treating bacterial infections, particularly bacterial vaginosis (BV) and related conditions, particularly endolysin polypeptides derived from Gardnerell...
|
|
WO/2022/100631A1 |
Provided are a lactobacillus crispatus strain for preventing and/or treating genital tract flora disorder related diseases, and an application thereof. The lactobacillus crispatus strain is lactobacillus crispatus LG55-27 obtained by scr...
|
|
WO/2022/100633A1 |
A Lactobacillus gasseri strain for the prevention and/or treatment of reproductive tract infections and/or reproductive tract flora disorders and the use thereof. The Lactobacillus gasseri is TM13-16, and has the deposit number GDMCC No:...
|
|
WO/2022/101948A1 |
The present invention relates to ω-3 polyunsaturated fatty acids for use in the prevention and treatment of male infertility in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments for the treatment of neo...
|
|
WO/2022/101303A1 |
This disclosure relates to combined oral preparations of N-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-diox
o-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-m
ethoxyurea (Compound 1), a...
|
|
WO/2022/100632A1 |
Lacticaseibacillus rhamnosus for preventing and/or treating diseases caused by the reproductive tract flora disorder and/or bone loss and an application thereof. The Lacticaseibacillus rhamnosus is OF44-15Ph10T, and the accession number ...
|
|
WO/2022/096254A1 |
The invention relates to a method for reducing the population of at least one intestinal and/or gastrointestinal bacteria species, the method comprising the following steps: a) providing a biological specimen which comprises bacteria of ...
|
|
WO/2022/098080A1 |
The present invention relates to a novel anti-Tie2 antibody or an antigen-binding fragment thereof, and use thereof. The present invention provides an antibody or an antigen-binding fragment thereof, comprising: at least one heavy chain ...
|
|
WO/2022/098085A1 |
The present invention relates to a body activation product using mineral particles, and more specifically, to a body activation product using mineral particles, wherein the product, which is manufactured by optimizing the size of the min...
|
|
WO/2022/092085A1 |
Provided is a pharmaceutical composition for treating tumors which is administered in combination with a PD-1 antagonist and contains 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin
-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H...
|
|
WO/2022/092910A1 |
The present invention relates to a crystal type II of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition including same. The crystal type II of the compound represented by chemical...
|
|
WO/2022/092914A1 |
The present invention relates to a crystal form IV of a compound represented by chemical formula 1, a preparation method therefor, and a pharmaceutical composition comprising same. The crystal form IV of a compound represented by chemica...
|
|
WO/2022/092913A1 |
The present invention relates to a crystalline form III of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystalline form III of the compound represented ...
|
|
WO/2022/092908A1 |
The present invention relates to an amorphous compound represented by chemical formula 1, a preparation method therefor, and a pharmaceutical composition comprising same. The amorphous compound represented by chemical formula 1 according...
|
|
WO/2022/092909A1 |
The present invention relates to crystalline form I of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form I of the compound represented by chemica...
|
|
WO/2022/091442A1 |
The purpose of the present invention is to provide a pharmaceutical composition for preventing and/or treating a viral disease in the vaginal or perivaginal area. The present invention provides a pharmaceutical composition for preventing...
|
